Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.

Thuijs DJFM, Kappetein AP, Serruys PW, Mohr FW, Morice MC, Mack MJ, Holmes DR Jr, Curzen N, Davierwala P, Noack T, Milojevic M, Dawkins KD, da Costa BR, Jüni P, Head SJ; SYNTAX Extended Survival Investigators.

Lancet. 2019 Oct 12;394(10206):1325-1334. doi: 10.1016/S0140-6736(19)31997-X. Epub 2019 Sep 2.

PMID:
31488373
2.

Clinical outcomes following implantation of the ION™ paclitaxel-eluting platinum chromium coronary stent in routine clinical practice: Results of the ION U.S. post-approval study.

Cannon LA, Kimmelstiel CD, White A, Hill R, Grady TP, Myers PR, Underwood P, Dawkins KD.

Catheter Cardiovasc Interv. 2018 Dec 30. doi: 10.1002/ccd.28044. [Epub ahead of print]

PMID:
30597737
3.

Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial.

Feldman TE, Reardon MJ, Rajagopal V, Makkar RR, Bajwa TK, Kleiman NS, Linke A, Kereiakes DJ, Waksman R, Thourani VH, Stoler RC, Mishkel GJ, Rizik DG, Iyer VS, Gleason TG, Tchétché D, Rovin JD, Buchbinder M, Meredith IT, Götberg M, Bjursten H, Meduri C, Salinger MH, Allocco DJ, Dawkins KD.

JAMA. 2018 Jan 2;319(1):27-37. doi: 10.1001/jama.2017.19132.

4.

Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial.

Kelly CR, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Rabinowitz A, Carrié D, Pompili V, Bouchard A, Saito S, Allocco DJ, Dawkins KD, Stone GW.

JACC Cardiovasc Interv. 2017 Dec 11;10(23):2392-2400. doi: 10.1016/j.jcin.2017.06.070.

5.

The impact of chronic kidney disease on outcomes following percutaneous coronary intervention versus coronary artery bypass grafting in patients with complex coronary artery disease: five-year follow-up of the SYNTAX trial.

Milojevic M, Head SJ, Mack MJ, Mohr FW, Morice MC, Dawkins KD, Holmes DR Jr, Serruys PW, Kappetein AP.

EuroIntervention. 2018 May 20;14(1):102-111. doi: 10.4244/EIJ-D-17-00620.

6.

Impact of bioresorbable versus permanent polymer on longterm vessel wall inflammation and healing: a comparative drug-eluting stent experimental study.

Wilson GJ, McGregor J, Conditt G, Shibuya M, Sushkova N, Eppihimer MJ, Hawley SP, Rouselle SD, Huibregtse BA, Dawkins KD, Granada JF.

EuroIntervention. 2018 Feb 20;13(14):1670-1679. doi: 10.4244/EIJ-D-17-00332.

7.

A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study.

Han Y, Liu H, Yang Y, Zhang J, Xu K, Fu G, Su X, Jiang T, Pang W, Chen J, Yuan Z, Li H, Wang H, Hong T, Liu H, Sun F, Allocco DJ, Zhang M, Dawkins KD.

EuroIntervention. 2017 Nov 20;13(10):1210-1217. doi: 10.4244/EIJ-D-17-00271.

8.

Safety and efficacy of a repositionable and fully retrievable aortic valve used in routine clinical practice: the RESPOND Study.

Falk V, Wöhrle J, Hildick-Smith D, Bleiziffer S, Blackman DJ, Abdel-Wahab M, Gerckens U, Linke A, Ince H, Wenaweser P, Allocco DJ, Dawkins KD, Van Mieghem NM.

Eur Heart J. 2017 Dec 1;38(45):3359-3366. doi: 10.1093/eurheartj/ehx297.

PMID:
28651336
9.

Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients.

Meredith IT, Dumonteil N, Blackman DJ, Tchétché D, Walters DL, Hildick-Smith D, Manoharan G, Harnek J, Worthley SG, Rioufol G, Lefèvre T, Modine T, Van Mieghem NM, Feldman T, Allocco DJ, Dawkins KD.

EuroIntervention. 2017 Sep 20;13(7):788-795. doi: 10.4244/EIJ-D-16-01024.

10.

Predictors of Paravalvular Regurgitation After Implantation of the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Valve (from the REPRISE II Trial Extended Cohort).

Blackman DJ, Meredith IT, Dumonteil N, Tchétché D, Hildick-Smith D, Spence MS, Walters DL, Harnek J, Worthley SG, Rioufol G, Lefèvre T, Houle VM, Allocco DJ, Dawkins KD.

Am J Cardiol. 2017 Jul 15;120(2):292-299. doi: 10.1016/j.amjcard.2017.04.026. Epub 2017 Apr 27.

PMID:
28535962
11.

Influence of practice patterns on outcome among countries enrolled in the SYNTAX trial: 5-year results between percutaneous coronary intervention and coronary artery bypass grafting.

Milojevic M, Head SJ, Mack MJ, Mohr FW, Morice MC, Dawkins KD, Holmes DR Jr, Serruys PW, Kappetein AP.

Eur J Cardiothorac Surg. 2017 Sep 1;52(3):445-453. doi: 10.1093/ejcts/ezx104.

PMID:
28520861
12.

Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort.

Dumonteil N, Meredith IT, Blackman DJ, Tchétché D, Hildick-Smith D, Spence MS, Walters DL, Harnek J, Worthley SG, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Houle VM, Allocco DJ, Dawkins KD.

EuroIntervention. 2017 Sep 20;13(7):796-803. doi: 10.4244/EIJ-D-16-01025.

13.

Does geographical variability influence five-year MACCE rates in the multicentre SYNTAX revascularisation trial?

Roy AK, Chevalier B, Lefèvre T, Louvard Y, Segurado R, Sawaya F, Spaziano M, Neylon A, Serruys PA, Dawkins KD, Kappetein AP, Mohr FW, Colombo A, Feldman T, Morice MC.

EuroIntervention. 2017 Sep 20;13(7):828-834. doi: 10.4244/EIJ-D-16-00991.

14.

Incidence, Characteristics, Predictors, and Outcomes of Repeat Revascularization After Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting: The SYNTAX Trial at 5 Years.

Parasca CA, Head SJ, Milojevic M, Mack MJ, Serruys PW, Morice MC, Mohr FW, Feldman TE, Colombo A, Dawkins KD, Holmes DR Jr, Kappetein PA; SYNTAX Investigators.

JACC Cardiovasc Interv. 2016 Dec 26;9(24):2493-2507. doi: 10.1016/j.jcin.2016.09.044.

15.

Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy.

Kereiakes DJ, Meredith IT, Masotti M, Carrié D, Moreno R, Erglis A, Mehta SR, Elhadad S, Berland J, Stein B, Airaksinen J, Jobe RL, Reitman A, Janssens L, Christen T, Dawkins KD, Windecker S.

EuroIntervention. 2017 Mar 20;12(16):1987-1994. doi: 10.4244/EIJ-D-16-00643.

16.

Fluorocopolymer-coated nitinol self-expanding paclitaxel-eluting stent: pharmacokinetics and vascular biology responses in a porcine iliofemoral model.

Hou D, Huibregtse BA, Eppihimer M, Stoffregen W, Kocur G, Hitzman C, Stejskal E, Heil J, Dawkins KD.

EuroIntervention. 2016 Aug 20;12(6):790-7. doi: 10.4244/EIJV12I6A128.

17.

1-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results of the REPRISE II Study.

Meredith IT, Walters DL, Dumonteil N, Worthley SG, Tchétché D, Manoharan G, Blackman DJ, Rioufol G, Hildick-Smith D, Whitbourn RJ, Lefèvre T, Lange R, Müller R, Redwood S, Feldman TE, Allocco DJ, Dawkins KD.

JACC Cardiovasc Interv. 2016 Feb 22;9(4):376-384. doi: 10.1016/j.jcin.2015.10.024.

18.

Causes of Death Following PCI Versus CABG in Complex CAD: 5-Year Follow-Up of SYNTAX.

Milojevic M, Head SJ, Parasca CA, Serruys PW, Mohr FW, Morice MC, Mack MJ, Ståhle E, Feldman TE, Dawkins KD, Colombo A, Kappetein AP, Holmes DR Jr.

J Am Coll Cardiol. 2016 Jan 5;67(1):42-55. doi: 10.1016/j.jacc.2015.10.043.

19.

One-Year Outcomes in "Real-World" Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS]).

Kandzari DE, Amjadi N, Caputo C, Rowe SK, Williams J, Tamboli HP, Christen T, Allocco DJ, Dawkins KD.

Am J Cardiol. 2016 Feb 15;117(4):539-545. doi: 10.1016/j.amjcard.2015.11.043. Epub 2015 Dec 7.

20.

Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.

Osnabrugge RL, Magnuson EA, Serruys PW, Campos CM, Wang K, van Klaveren D, Farooq V, Abdallah MS, Li H, Vilain KA, Steyerberg EW, Morice MC, Dawkins KD, Mohr FW, Kappetein AP, Cohen DJ; SYNTAX trial investigators.

Heart. 2015 Dec;101(24):1980-8. doi: 10.1136/heartjnl-2015-307578. Epub 2015 Nov 9.

PMID:
26552756
21.

The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery Trial and Registry.

Parasca CA, Head SJ, Mohr FW, Mack MJ, Morice MC, Holmes DR Jr, Feldman TE, Colombo A, Dawkins KD, Serruys PW, Kappetein AP; SYNTAX Investigators.

J Thorac Cardiovasc Surg. 2015 Sep;150(3):597-606.e2. doi: 10.1016/j.jtcvs.2015.05.010. Epub 2015 May 8.

22.

The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer safety study.

Wilson GJ, Marks A, Berg KJ, Eppihimer M, Sushkova N, Hawley SP, Robertson KA, Knapp D, Pennington DE, Chen YL, Foss A, Huibregtse B, Dawkins KD.

Catheter Cardiovasc Interv. 2015 Nov 15;86(6):E247-57. doi: 10.1002/ccd.25993. Epub 2015 May 23.

PMID:
26009986
23.

Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study.

Watkins S, Oldroyd KG, Preda I, Holmes DR Jr, Colombo A, Morice MC, Leadley K, Dawkins KD, Mohr FW, Serruys PW, Feldman TE.

EuroIntervention. 2015 Apr;10(12):1402-8. doi: 10.4244/EIJV10I12A244.

24.

Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial.

Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, Feldman RL, Stein B, Dubois C, Grady T, Saito S, Kimura T, Christen T, Allocco DJ, Dawkins KD.

Circ Cardiovasc Interv. 2015 Apr;8(4). pii: e002372. doi: 10.1161/CIRCINTERVENTIONS.114.002372.

25.

Long-term follow-up of the platinum chromium TAXUS Element (ION) stent: The PERSEUS Workhorse and Small Vessel trial five-year results.

Kereiakes DJ, Cannon LA, Dauber I, Ball M, Bertolet B, Foster M, Nersesov AY, Underwood PL, Allocco DJ, Dawkins KD.

Catheter Cardiovasc Interv. 2015 Nov 15;86(6):994-1001. doi: 10.1002/ccd.25877. Epub 2015 Feb 25.

PMID:
25678402
26.

PLATINUM China: a prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions.

Gao R, Han Y, Yang Y, Zhang J, Hou Y, Wang H, Li H, Fang Q, Yu B, Xu B, Allocco DJ, Dawkins KD.

Catheter Cardiovasc Interv. 2015 Mar;85 Suppl 1:716-23. doi: 10.1002/ccd.25859. Epub 2015 Feb 18.

PMID:
25631909
27.

One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study.

Thomas MR, Birkemeyer R, Schwimmbeck P, Legrand V, Moreno R, Briguori C, Werner N, Bramucci E, Ungi I, Richardt G, Underwood PL, Dawkins KD.

EuroIntervention. 2015 Mar;10(11):1267-71. doi: 10.4244/EIJY15M01_07.

28.

One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE).

Tamburino C, Capodanno D, Erglis A, Menown IB, Horváth IG, Moreno R, Gilbert TJ, Crowley JJ, Calabria P, Allocco DJ, Dawkins KD.

EuroIntervention. 2015 Mar;10(11):1261-6. doi: 10.4244/EIJY15M01_01.

29.

Serial intravascular ultrasound analysis of stent strut distribution and fracture: an integrated analysis of the taxus IV, V, and VI trials.

Pracon R, Opolski MP, Mintz GS, Pregowski J, Kruk M, Popma JJ, Mandinov L, Wang H, Ellis SG, Grube E, Dawkins KD, Stone GW, Weissman NJ.

J Invasive Cardiol. 2014 Oct;26(10):501-11.

30.

Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study.

Meredith Am IT, Walters DL, Dumonteil N, Worthley SG, Tchétché D, Manoharan G, Blackman DJ, Rioufol G, Hildick-Smith D, Whitbourn RJ, Lefèvre T, Lange R, Müller R, Redwood S, Allocco DJ, Dawkins KD.

J Am Coll Cardiol. 2014 Sep 30;64(13):1339-48. doi: 10.1016/j.jacc.2014.05.067.

31.

Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.

Cohen DJ, Osnabrugge RL, Magnuson EA, Wang K, Li H, Chinnakondepalli K, Pinto D, Abdallah MS, Vilain KA, Morice MC, Dawkins KD, Kappetein AP, Mohr FW, Serruys PW; SYNTAX Trial Investigators.

Circulation. 2014 Sep 30;130(14):1146-57. doi: 10.1161/CIRCULATIONAHA.114.009985. Epub 2014 Aug 1.

PMID:
25085960
32.

Prognostic value of site SYNTAX score and rationale for combining anatomic and clinical factors in decision making: insights from the SYNTAX trial.

Zhang YJ, Iqbal J, Campos CM, Klaveren DV, Bourantas CV, Dawkins KD, Banning AP, Escaned J, de Vries T, Morel MA, Farooq V, Onuma Y, Garcia-Garcia HM, Stone GW, Steyerberg EW, Mohr FW, Serruys PW.

J Am Coll Cardiol. 2014 Aug 5;64(5):423-32. doi: 10.1016/j.jacc.2014.05.022.

33.

Stenting for ST-segment elevation myocardial infarction is associated with less neointimal hyperplasia in the pooled IVUS analysis from HORIZONS-AMI and the TAXUS IV and V and ATLAS workhorse, long lesion, and direct stent studies.

Kobayashi N, Maehara A, Allocco D, Witzenbichler B, Ellis SG, Turco MA, Ormiston JA, Guagliumi G, Jiang S, McAndrew TC, Dawkins KD, Stone GW, Mintz GS, Weissman NJ.

Coron Artery Dis. 2014 Nov;25(7):575-81. doi: 10.1097/MCA.0000000000000131.

PMID:
24911615
34.

Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions.

Teirstein PS, Meredith IT, Feldman RL, Rabinowitz AC, Cannon LA, Lee TC, Dens J, Dubois CL, Mooney MR, Pompili VJ, Saito S, Allocco DJ, Dawkins KD, Stone GW.

Catheter Cardiovasc Interv. 2015 Feb 1;85(2):207-15. doi: 10.1002/ccd.25565. Epub 2014 Jul 4.

PMID:
24905795
35.

Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial.

Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, Morice MC, Holmes DR Jr, Feldman TE, Ståhle E, Underwood P, Dawkins KD, Kappetein AP, Mohr FW.

Eur Heart J. 2014 Oct 21;35(40):2821-30. doi: 10.1093/eurheartj/ehu213. Epub 2014 May 21.

PMID:
24849105
36.

Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: an analysis of the SYNTAX study.

Bourantas CV, Zhang YJ, Garg S, Mack M, Dawkins KD, Kappetein AP, Mohr FW, Colombo A, Holmes DR, Ståhle E, Feldman T, Morice MC, de Vries T, Morel MA, Serruys PW.

Catheter Cardiovasc Interv. 2015 Feb 1;85(2):199-206. doi: 10.1002/ccd.25545. Epub 2014 May 27.

PMID:
24824456
37.

Differences in baseline characteristics, practice patterns and clinical outcomes in contemporary coronary artery bypass grafting in the United States and Europe: insights from the SYNTAX randomized trial and registry.

Head SJ, Parasca CA, Mack MJ, Mohr FW, Morice MC, Holmes DR Jr, Feldman TE, Dawkins KD, Colombo A, Serruys PW, Kappetein AP; SYNTAX Investigators.

Eur J Cardiothorac Surg. 2015 Apr;47(4):685-95. doi: 10.1093/ejcts/ezu197. Epub 2014 May 12.

PMID:
24819358
38.

The EPIC nitinol stent system in the treatment of iliac artery lesions: one-year results from the ORION clinical trial.

Clair DG, Adams J, Reen B, Feldman R, Starr J, Diaz-Cartelle J, Dawkins KD.

J Endovasc Ther. 2014 Apr;21(2):213-22. doi: 10.1583/13-4560.1.

PMID:
24754280
39.

Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial.

Morice MC, Serruys PW, Kappetein AP, Feldman TE, Ståhle E, Colombo A, Mack MJ, Holmes DR, Choi JW, Ruzyllo W, Religa G, Huang J, Roy K, Dawkins KD, Mohr F.

Circulation. 2014 Jun 10;129(23):2388-94. doi: 10.1161/CIRCULATIONAHA.113.006689. Epub 2014 Apr 3.

PMID:
24700706
40.

Experimental evaluation of efficacy and healing response of everolimus-eluting stents in the familial hypercholesterolemic swine model: a comparative study of bioabsorbable versus durable polymer stent platforms.

Tellez A, Seifert PS, Donskoy E, Sushkova N, Pennington DE, Milewski K, Krueger CG, Kaluza GL, Eppihimer MJ, Huibregtse BA, Dawkins KD, Granada JF.

Coron Artery Dis. 2014 May;25(3):198-207. doi: 10.1097/MCA.0000000000000099.

PMID:
24642807
41.

Response to letter regarding article, "Quantification of incomplete revascularization and its association with five-year mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial: validation of the residual SYNTAX Score".

Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, Holmes DR, Mack M, Morice MC, Ståhle E, Colombo A, de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW.

Circulation. 2014 Feb 25;129(8):e355-6. doi: 10.1161/CIRCULATIONAHA.114.008026. No abstract available.

PMID:
24566072
42.

Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM Trial).

Meredith IT, Teirstein PS, Bouchard A, Carrié D, Möllmann H, Oldroyd KG, Hall J, Allocco DJ, Dawkins KD, Stone GW.

Am J Cardiol. 2014 Apr 1;113(7):1117-23. doi: 10.1016/j.amjcard.2013.12.011. Epub 2014 Jan 14.

PMID:
24530167
43.

Revascularization of lower extremity chronic total occlusions with a novel intraluminal recanalization device: results of the ReOpen study.

Bosiers M, Diaz-Cartelle J, Scheinert D, Peeters P, Dawkins KD.

J Endovasc Ther. 2014 Feb;21(1):61-70. doi: 10.1583/12-4083R.1.

PMID:
24502485
44.

Japanese and non-Japanese patient outcomes in the PLATINUM randomized trial comparing the PROMUS Element and XIENCE V everolimus-eluting stents.

Saito S, Hagiwara N, Seki A, Igarashi K, Muramatsu T, Yajima J, Yokoi H, Nakamura M, Fujii K, Isshiki T, Stone GW, Teirstein PS, Meredith IT, Allocco DJ, Dawkins KD.

J Cardiol. 2014 Aug;64(2):105-12. doi: 10.1016/j.jjcc.2013.12.003. Epub 2014 Jan 23.

45.

Impact of 3-dimensional bifurcation angle on 5-year outcome of patients after percutaneous coronary intervention for left main coronary artery disease: a substudy of the SYNTAX trial (synergy between percutaneous coronary intervention with taxus and cardiac surgery).

Girasis C, Farooq V, Diletti R, Muramatsu T, Bourantas CV, Onuma Y, Holmes DR, Feldman TE, Morel MA, van Es GA, Dawkins KD, Morice MC, Serruys PW.

JACC Cardiovasc Interv. 2013 Dec;6(12):1250-60. doi: 10.1016/j.jcin.2013.08.009.

46.

Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study.

Meredith IT, Worthley SG, Whitbourn RJ, Antonis P, Montarello JK, Newcomb AE, Lockwood S, Haratani N, Allocco DJ, Dawkins KD.

EuroIntervention. 2014 Mar 20;9(11):1264-70. doi: 10.4244/EIJV9I11A216.

47.

Short-term and long-term clinical impact of stent thrombosis and graft occlusion in the SYNTAX trial at 5 years: Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial.

Farooq V, Serruys PW, Zhang Y, Mack M, Ståhle E, Holmes DR, Feldman T, Morice MC, Colombo A, Bourantas CV, de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW.

J Am Coll Cardiol. 2013 Dec 24;62(25):2360-2369. doi: 10.1016/j.jacc.2013.07.106. Epub 2013 Oct 16.

48.

Incidence, correlates, and significance of abnormal cardiac enzyme rises in patients treated with surgical or percutaneous based revascularisation: a substudy from the Synergy between Percutaneous Coronary Interventions with Taxus and Cardiac Surgery (SYNTAX) Trial.

Farooq V, Serruys PW, Vranckx P, Bourantas CV, Girasis C, Holmes DR, Kappetein AP, Mack M, Feldman T, Morice MC, Colombo A, Morel MA, de Vries T, Dawkins KD, Mohr FW, James S, Ståhle E.

Int J Cardiol. 2013 Oct 15;168(6):5287-92. doi: 10.1016/j.ijcard.2013.08.013. Epub 2013 Aug 14.

PMID:
23993326
49.

Boston Scientific Lotus valve.

Meredith IT, Hood KL, Haratani N, Allocco DJ, Dawkins KD.

EuroIntervention. 2012 Sep;8 Suppl Q:Q70-4. doi: 10.4244/EIJV8SQA12.

PMID:
22995115
50.

Impact of stent surface on thrombogenicity and vascular healing: a comparative analysis of metallic and polymeric surfaces.

Eppihimer MJ, Sushkova N, Grimsby JL, Efimova N, Kai W, Larson S, Forsyth B, Huibregtse BA, Dawkins KD, Wilson GJ, Granada JF.

Circ Cardiovasc Interv. 2013 Aug;6(4):370-7. doi: 10.1161/CIRCINTERVENTIONS.113.000120. Epub 2013 Jul 30.

PMID:
23899869

Supplemental Content

Loading ...
Support Center